

Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)

NCT07327840

Status	RECRUITING
Phase	Phase 2
Sponsor	Kylonova (Xiamen) Biopharma co., LTD.
Enrollment	204 participants

Key Eligibility Criteria

Inclusion (2)

- Age 18 to 80 years
- Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)

Exclusion (4)

- Have moderate to severe heart failure (New York Heart Association [NYHA] Functional Classification III or IV during Screening) or last known left ventricular ejection fraction $<30\%$
- Have uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg)
- Have uncontrolled cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization
- Have had any malignancy within 5 years prior to randomization (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma that has been successfully treated)

Locations (43 total)

Peking University First Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Baotou Medical College, Baotou, China
Beijing Anzhen Hospital, Beijing, China
... and 40 more locations